期刊文献+

我国发展药物大品种的关键因素与政策探讨

Key Factors and Regulation Policies for Development of Drug Superstars in China
下载PDF
导出
摘要 目的:探讨我国发展药物大品种的关键因素和规制政策。方法:选取政府、企业、学术机构等单位的专家学者进行访谈,然后采用扎根理论分析访谈资料。结果:界定出药物大品种的概念范围,明确了我国建立药物大品种的必要性,分析出药物大品种改造的产业政策,并提出我国药物大品种改造的政策规制模型。结论:政府应建立政策、完善制度,引导企业发展;企业应加强自身创新能力、开拓国际市场,推进大品种的改造。 Objective: To discuss key factors and regulation policies for development of drug superstars in China. Methods: Interviews were conducted with several experts from governments, enterprises and research institutions, and then the interview data were analyzed by grounded theory. Results: The concept of drug superstars was defined, the necessity of drug superstars was clarified, the industry policy for modification of drug superstars was analyzed, and the policy regulation model for modification of drug superstars was proposed. Conclusion: Governments should establish policy and improve system construction to guide enterprises to develop drug superstars. And enterprises should enhance their innovation capability and explore the international market to promote the reform of drug superstars in China.
出处 《中国药事》 CAS 2015年第11期1117-1124,共8页 Chinese Pharmaceutical Affairs
关键词 药物大品种 扎根理论 专家访谈 政策规制 drug superstars grounded theory interview with experts regulation policy
  • 相关文献

参考文献12

  • 1张永祥.“重大新药创制”重大专项实施对我国新药研究开发的影响[J].中国药理学通报,2009,25(10):8-10.
  • 2胡振,刘广南.我国重大新药创制与策略分析[J].经营管理者,2009(19):97-97. 被引量:1
  • 3中国药学会.中国生物医学科学正在酝酿一系列重大的突破[EB/OL].(2007-09-03)[2015-06-05].http://www.ebiotrade.com/newsf/2007-9/20079393740.htm.
  • 4Glaser B.G, Strauss A.L. The Discovery of Grounded Theory[M]. Chicago: Aldine, 1967.
  • 5凯西卡麦兹.构建扎根理论:质性研究实践指南[M].边国英,陈向明,译.重庆:重庆大学出版社,2009:55-91.
  • 6苏伟萍,宋瑞霖,王一涛,史录文.发展我国仿制药大品种的对策[J].中国新药杂志,2011,20(3):200-203. 被引量:4
  • 7胡春丽,张珂良,汪丽.从中美两国药品质量标准现状看我国药品标准管理存在的问题[J].中国药事,2012,26(4):328-331. 被引量:18
  • 8国家发展和改革委员会.发改价格[2015]904号关于印发推进药品价格改革意见的通知[S].2015.
  • 9Aitken M, Berndt ER, Cutler DM. Prescription Drug Spending Trends in the United States: Looking Beyond the Turning Point[J]. Health Affair (Millwood), 2009, 28 (1) : 151-160.
  • 10Danzon PM, Furukawa MF. International Prices and Availability of Pharmaceuticals in 2005[J]. Health Affair (Millwood), 2008, 27 (1) : 221-233.

二级参考文献21

  • 1路文志.品牌价值是民族制药企业的持久动力[J].医学信息(西安下半月),2005(5):6-9. 被引量:1
  • 2王平,王国荣.浅析我国药品标准及其在新时期的地位与作用[J].中国药事,2006,20(1):22-25. 被引量:18
  • 3陆玲宝,许明哲.美国药典的历史沿革和现状[J].中国药事,2007,21(5):360-361. 被引量:10
  • 4药品管理法[S].中华人民共和国主席令第18号,1984.
  • 5FELDMAN C. Generic drug superstars [ J/OL ]. Fortune, (2009 - 08-05). [2010 -03 - 10]. http://money. cnn. com/2009/ 08/05/news/companies/top_generic_drugs.fortune/.
  • 6倪钎.印度制药产业深度分析[N].医药经济报,2006-07-12(008).
  • 7VOGEL RJ,JOISH V. The potential unintended economic conse- quences of the medicine equity and drug safety act of 2000 [ J]. Clin Ther,2001,23 ( 4 ) :629 - 643.
  • 8CIMONS M. Drug costs threaten patent protection[ J]. Nat Med, 2003,9(1): 9-12.
  • 9DANZON PM,TOWSE A. Differential pricing for pharmaceuticals: reconciling access,R&D and patents[ J ]. Int J Health Care Finance Econ ,2003,3 ( 3 ) : 183 - 205.
  • 10MRAZEK MF,MOSSIALOS E. Increasing demand while decreasing costs of generic medicines [ J ]. Lancet, 2000,356 ( 9244 ) : 1784 - 1785.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部